BSc (Hons) (Glasgow, 1977); PhD (Glasgow, 1980)
Senior Research Fellow
- About
-
- Email Address
- c.harrington@abdn.ac.uk
- Telephone Number
- +44 (0)1224 438563
- Office Address
Liberty Building, Institute of Medical Sciences, Foresterhill Road, Aberdeen AB25 2ZP United Kingdom
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Charlie Harrington graduated in Microbiology from Glasgow University where he developed an interest in chemical microbiology and the study of microbial cell walls. He completed his PhD working with Dr Julia Douglas on cell wall synthesis in yeast and followed with a one-year NIH-funded Fellowship with Dr Wilf Arnold in Kansas City, Missouri studying enzymes within the yeast cell envelope. After this, Charlie joined Professor Sir James Baddiley in the Department of Biochemistry at the University of Cambridge as a Research Fellow, where he spent four years investigating the synthesis of bacterial cell wall polymers. Dr Harrington then spent over two years at Murex Medical Research Ltd., Cambridge, developing diagnostic tests for microbial diseases, including methicillin-resistant Staphylococcus aureus and sexually transmitted diseases. This combined monoclonal antibody technology with his knowledge of the microbial cell surface.
In 1988, he joined Claude Wischik working at the Medical Research Council’s Laboratory of Molecular Biology. Working in the Cambridge Brain Bank Laboratory over a period of 10 years. During this time, Wischik, Harrington and colleagues developed an assay for screening agents having the potential to prevent the tau pathology that is the hallmark of Alzheimer’s disease. Charlie moved with Professor Wischik, in 1998, to the University of Aberdeen, where he was appointed as a Senior Research Fellow.
The Alzheimer's research was translated to the clinic, through a spin-out company, TauRx Therapeutics, who are conducting phase 3 trials of hydromethylthionine. Dr Harrington is Chief Scientific Officer for TauRx Therapeutics Ltd responsible for the non-clinical activities of the company.
Qualifications
- BSc (Hons) Microbiology1977 - University of Glasgow
- PhD Microbiology1980 - University of Glasgow
Latest Publications
LETC inhibits α-Syn aggregation and ameliorates motor deficiencies in the L62 mouse model of synucleinopathy
European Journal of Pharmacology, 176505Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.ejphar.2024.176505
Solubility of α-synuclein species in the L62 mouse model of synucleinopathy
Scientific Reports, vol. 14, 6239Contributions to Journals: ArticlesApathy-like behaviour in tau mouse models of Alzheimer’s disease and frontotemporal dementia
Behavioural Brain Research, vol. 456, 114707Contributions to Journals: ArticlesA Meta-Analysis on Presynaptic Changes in Alzheimer's Disease
Journal of Alzheimer's Disease, vol. 97, no. 1, pp. 145-162Contributions to Journals: ArticlesAssays for the Screening and Characterization of Tau Aggregation Inhibitors
Methods in molecular biology (Clifton, N.J.), vol. 2754, pp. 93-104Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/978-1-0716-3629-9_5
- Research
-
Research Overview
Dr Harrington has research interests in the neurodegenerative diseases and, in particular, Alzheimer’s disease. His main focus has been on the biology of tau protein in aging and in Alzheimer’s disease. Dr Harrington’s research is aimed at diseases that are characterised by protein aggregation and methods by which these processes might be prevented.
- Publications
-
Page 7 of 10 Results 61 to 70 of 94
The molecular pathology of Alzheimer's disease
Neuroimaging Clinics of North America, vol. 22, no. 1, pp. 11-22Contributions to Journals: Literature Reviews- [ONLINE] DOI: https://doi.org/10.1016/j.nic.2011.11.003
3,7-diamino-10H-phenothiazine salts and their use: WO2007110627
Patents: PatentsStripline resonator and preamplifier for preclinical magnetic resonance imaging at 4.7 T
Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 24, no. 6, pp. 331-337Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1007/s10334-011-0273-8
3,6-Disubstituted xanthylium salts
Patents: PatentsMethods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC): methods of treatment of a tauopathy condition comprising the use of thioninium compounds
Patents: PatentsLigands for aggregated tau molecules: WO2010034982
Patents: PatentsRationale for tau aggregation inhibitor therapy in Alzheimer's disease and other tauopathies
Emerging drugs and targets for Alzheimer's disease: Volume 1: Beta-Amyloid, Tau Protein and Glucose Metabolism. Martinez, A. (ed.), pp. 210-232, 23 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1039/9781849731065
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/4066/1/Wischik_2010_RSC_Chapter.pdf
Lewy body variant of Alzheimer's disease: selective neocortical loss of t-SNARE proteins and loss of MAP2 and alpha-synuclein in medial temporal lobe
The Scientific World Journal, vol. 9, pp. 1463-1475Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1100/tsw.2009.151
What is the molecular pathology that underlies hippocampal memory decline?
Journal of Neurology, Neurosurgery & Psychiatry, vol. 80, no. 7, pp. 703Contributions to Journals: EditorialsTherapeutic Use of Diaminophenothiazines: WO2009044127
Patents: Patents